Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effects of AZD6793 in adults with moderate to very severe chronic obstructive pulmonary disease COPD. This Phase IIb study compares two different doses of AZD6793 to placebo tablets to assess their efficacy and safety. The study is randomized, double-blind, placebo-controlled, and involves about 970 participants worldwide. Participants will be randomly assigned to one of three groups two different doses of AZD6793 or a matching placebo. The study lasts for 24 weeks, during which participants will take oral tablets of their assigned treatment. The trial aims to measure how well AZD6793 works to reduce COPD exacerbations compared to placebo. Throughout the study, participants will have regular assessments including lung function tests, symptom questionnaires, and blood tests to measure drug levels. Researchers will monitor the rate of COPD exacerbations, lung function changes, and symptom scores over 24 weeks. Safety and tolerability of the treatments will also be closely observed during this period.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of tezepelumab, a biological drug, in adults aged 40 to 80 with moderate to very severe chronic obstructive pulmonary disease COPD. This Phase 3, randomized, double-blind, placebo-controlled study includes participants who have experienced worsening COPD symptoms despite inhaled maintenance therapy. The study aims to reduce the rate of moderate or severe COPD exacerbations, which are episodes when symptoms worsen significantly. Participants will receive monthly subcutaneous injections of either one of two doses of tezepelumab or a matching placebo for a minimum of 52 weeks and up to 76 weeks. After the treatment period, there is a 12-week safety follow-up without treatment. The study compares tezepelumabs effects to placebo to evaluate its impact on lung function, COPD symptoms, and exacerbation frequency. Throughout the study, participants will undergo regular assessments including lung function tests, symptom questionnaires, and blood tests to monitor immune response and drug levels. Researchers will track COPD exacerbations and quality of life changes using tools like the St. Georges Respiratory Questionnaire and COPD Assessment Test. Safety will be monitored during and after treatment, with the entire participation lasting up to about 88 weeks including follow-up.
Actively Recruiting
Researchers are evaluating two types of PHMB-impregnated biocellulose wound dressings, SuprasorbXPHMB Pro and SuprasorbXPHMB, to compare their performance and safety in treating patients with infected venous leg ulcers. This multicenter, open-label, randomized parallel group controlled study focuses on patients with slight to moderate wound exudation, aiming to improve treatment outcomes for this condition. Patients with high wound exudation may first undergo a 7-day run-in period receiving superabsorbent dressings and monitored compression therapy, including systemic antimicrobial drugs if needed. After this, eligible patients will be randomly assigned to receive either SuprasorbXPHMB Pro or SuprasorbXPHMB dressings. All patients will receive their assigned dressing for about 21 days, or until complete wound healing occurs, alongside continued compression therapy and systemic antimicrobial treatment as required. Participants will be assessed at baseline, interim, and end-of-treatment visits for wound characteristics, exudation levels, infection status, pain, quality of life, and product usability. Dressing changes may occur as needed during the study. The main outcome measured is the rate and severity of skin maceration after three weeks of treatment. The study lasts about three weeks, after which further treatment is managed outside the trial.